| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Dementia Research Laboratory (Drs. Minger and Francis), Centre for Neuroscience Research, GKT School of Biomedical Sciences, King’s College London; and the Departments of Neuropathology (M.M. Esiri, B. McDonald, and J. Carter) and Psychiatry (J. Keene and T. Hope), and Ethox, Institute of Health Sciences (T. Hope), University of Oxford, United Kingdom.
Address correspondence and reprint requests to Dr. Paul T. Francis, Dementia Research Laboratory, Centre for Neuroscience Research, GKT School of Biomedical Sciences, Hodgkin Building, King’s College London, Guy’s Campus, St Thomas Street, London SE1 1UL, UK; e-mail: paul.francis{at}kcl.ac.uk
BACKGROUND: Noncognitive behavioral changes such as depression, aggressive behavior, psychosis, and overactivity occur frequently in patients with dementia, in addition to cognitive impairment, and often determine the need for institutionalization. The biochemical basis of such changes is poorly understood. Clinical trial data indicate that cholinomimetics improve noncognitive behaviors. This study investigated the relationship between markers of the cholinergic and dopaminergic neurotransmitter systems and noncognitive behavioral symptoms assessed during the course of dementing illness. Method:— Brains from 46 patients with dementia (36 with AD and 10 with mixed or other dementias using Consortium to Establish a Registry for AD criteria) were examined together with 32 normal controls. The patients with dementia had been evaluated every 4 months, often over several years, for cognitive performance (Mini-Mental State Examination) and behavior (Present Behavioral Examination). Concentrations of dopamine (DA) and major metabolites, choline acetyltransferase activity (ChAT), and density (Bmax) of DA D1 receptors in frontal and temporal cortex were studied by radioligand binding protocols. None of the patients was receiving cholinomimetic drugs.
RESULTS: ChAT activity, but no other neurochemical markers, was reduced in AD compared with controls. Loss of ChAT activity correlated with cognitive impairment. Lowered ChAT activity also correlated with increasing overactivity in patients with dementia in both frontal and temporal cortex whereas ChAT:DA and ChAT:D1 ratios in temporal cortex correlated negatively with aggressive behavior.
CONCLUSIONS: Disturbance of the cholinergic system may underlie both cognitive and some noncognitive behavioral changes in dementia, providing a basis for rational therapy.–1467
This article has been cited by other articles:
|
|
 |
|
  C. A. Orengo, J. Khan, M. E. Kunik, A. L. Snow, R. Morgan, A. Steele, J. A. Cully, and D. P. Graham Aggression in Individuals Newly Diagnosed With Dementia American Journal of Alzheimer's Disease and Other Dementias, June 1, 2008; 23(3): 227 - 232. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Bourbonnais and F. Ducharme Screaming in elderly persons with dementia: A critical review of the literature Dementia, May 1, 2008; 7(2): 205 - 225. [Abstract] [PDF]
|
|
|
|
 |
|
 M. T. Fodero-Tavoletti, D. P. Smith, C. A. McLean, P. A. Adlard, K. J. Barnham, L. E. Foster, L. Leone, K. Perez, M. Cortes, J. G. Culvenor, et al. In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies J. Neurosci., September 26, 2007; 27(39): 10365 - 10371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Ally, G. E. Jones, J. A. Cole, and A. E. Budson Sensory Gating in Patients With Alzheimer's Disease and Their Biological Children American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 439 - 447. [Abstract] [PDF]
|
|
|
|
 |
|
 C. W. Ritchie, D. Ames, T. Clayton, and R. Lai Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease Am J Geriatr Psychiatry, August 1, 2004; 12(4): 358 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Holmes, D. Wilkinson, C. Dean, S. Vethanayagam, S. Olivieri, A. Langley, N. D. Pandita-Gunawardena, F. Hogg, C. Clare, and J. Damms The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease Neurology, July 27, 2004; 63(2): 214 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mesulam The Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show? Learn. Mem., January 1, 2004; 11(1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Terry Jr and J. J. Buccafusco The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 821 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-H. Trinh, J. Hoblyn, S. Mohanty, and K. Yaffe Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in Alzheimer Disease: A Meta-analysis JAMA, January 8, 2003; 289(2): 210 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. P. Lai, O. -F. Lai, J. Keene, M. M. Esiri, P. T. Francis, T. Hope, and C. P.L.-H. Chen Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex Neurology, September 11, 2001; 57(5): 805 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Feldman, S. Gauthier, J. Hecker, B. Vellas, P. Subbiah, and E. Whalen A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology, August 28, 2001; 57(4): 613 - 620. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
